---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019685"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:30:44.625587+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio Q1 net loss $30.9M vs prior-year net income; cash $231.6M

## Summary
- Net loss of $30.9M ($0.72 loss per share) vs net income of $4.6M in Q1 2022.
- Cash, cash equivalents and investments $231.6M at March 31, expected to fund ops into H1 2025.
- R&D expenses rose to $26.8M from $13.5M YoY, driven by increased CDMO and headcount costs.
- Plan to discuss FDA path for ADI-001 pivotal study in Q2 2023; initiate study in Q4 2023.
- ADI-270 preclinical data at ASGCT May 18; IND for ADI-925 expected H2 2023.

## SEC filing metadata
- accession: 0000950170-23-019685
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017023019685/0000950170-23-019685-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017023019685/acet-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019685
- JSON: https://secwatch.observer/filing/0000950170-23-019685.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019685.txt

## Key facts
- Earnings Releases
  Adicet Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023 was $30.9 million, or a net loss of $0.72 per basic and diluted share, EPS $0.72 per basic and diluted share.
  - Period: the quarter ended March 31, 2023
  - Net income: Net loss for the three months ended March 31, 2023 was $30.9 million, or a net loss of $0.72 per basic and diluted share
  - EPS: $0.72 per basic and diluted share
  - Result: reported results
  source text: Adicet Bio, Inc. announced its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720580/000095017023019685/0000950170-23-019685-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.